Adicet Bio 将来の成長

NasdaqGM:ACET - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	4	-133	-69	-123	7
12/31/2025	3	-127	-81	-107	8
12/31/2024	N/A	-121	-100	-97	8
9/30/2024	N/A	-118	-93	-92	N/A
6/30/2024	N/A	-137	-93	-91	N/A
3/31/2024	N/A	-140	-95	-92	N/A
12/31/2023	N/A	-143	-98	-94	N/A
9/30/2023	N/A	-143	-100	-89	N/A
6/30/2023	N/A	-115	-98	-83	N/A
3/31/2023	N/A	-105	-89	-73	N/A
12/31/2022	25	-70	-62	-45	N/A
9/30/2022	30	-56	-53	-39	N/A
6/30/2022	34	-48	-49	-34	N/A
3/31/2022	39	-36	-47	-32	N/A
12/31/2021	10	-62	-64	-51	N/A
9/30/2021	10	-55	-61	-51	N/A
6/30/2021	9	-56	-52	-49	N/A
3/31/2021	12	-54	-50	-48	N/A
12/31/2020	18	-37	-43	-42	N/A
9/30/2020	14	-34	-37	-35	N/A
6/30/2020	4	-34	-36	-35	N/A
3/31/2020	0	-28	-30	-29	N/A
12/31/2019	1	-28	-29	-28	N/A
12/31/2018	8	-9	-19	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ACET今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ACET今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ACET今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ACETの収益 ( 79.7% ) US市場 ( 9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ACETの収益 ( 79.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ACETの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Adicet Bio 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 18% to US$12.80

Price target decreased by 15% to US$18.29

Price target decreased by 14% to US$23.29

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Consensus revenue estimates increase by 180%, EPS downgraded

Recent updates

Adicet Bio, Inc. Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio: Microcap With A High Risk To Reward Ratio

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Price target decreased by 18% to US$12.80

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?

Price target decreased by 15% to US$18.29

New minor risk - Market cap size

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Price target decreased by 14% to US$23.29

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Price target decreased by 7.8% to US$25.44

Consensus EPS estimates upgraded to US$2.42 loss

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates increase by 180%, EPS downgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Chief Technology Officer notifies of intention to sell stock

Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation

Consensus forecasts updated

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

CEO, President & Director notifies of intention to sell stock

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021)

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio

Now 23% undervalued after recent price drop

Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Senior VP & Chief Scientific Officer notifies of intention to sell stock

Adicet Bio: A First Take

Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

Consensus revenue estimates increase by 42%

Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

High number of new and inexperienced directors

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Chief Medical Officer & Senior VP notifies of intention to sell stock

Consensus forecasts updated

Consensus revenue estimates fall by 31%

We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate

Full year 2021 earnings: EPS and revenues exceed analyst expectations